Ambry Genetics
Dr. Hurley will provide an overview of psychosocial challenges faced by patients deciding to undergo genetic testing. Her presentation will combine research findings from psychosocial research and case illustrations from twenty years of providing psychotherapy to genetic counseling patients. She will provide tips on communication strategies as well as common pitfalls to avoid, and discuss advantages of creating an “information plan” based on patients’ needs, preferences, and ability to absorb emotionally challenging information. Clinical examples will be drawn from Dr. Hurley’s specialty in hereditary cancer risk, with the discussion of how psychosocial issues in genetic testing are relevant across a broad range of conditions, from the prenatal setting to other pediatric- and adult-onset hereditary syndromes.
Watch Now
Multi-omics approaches integrate multiple omics data generated from cancer patients to better understand the molecular and clinical features of cancer. Multi-omics technologies, including genomics, proteomics, and metabolomics, have also been included in clinical trials to understand the response to immunotherapy and the mechanisms of drug resistance.
Watch Now
Halo Labs
Subvisible particle analysis is a key predictor of protein drug stability and a key formulation, quality metric. However, current methods use large volumes of precious protein solutions and are labor- and time-intensive, making this data inaccessible during late-stage candidate screening or early in formulation. Moreover, regulatory agencies are tightly enforcing subvisible particle content in biopharma formulations at unprecedented levels, making early detection of subvisible particles, like protein aggregates, a key analytical priority.
Watch Now
statnews
Clinical trial data can be remarkably (and unnecessarily) difficult to read. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading scientific results — and you can learn it.
Watch Now